Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/S1473-3099(24)00600-5 | DOI Listing |
Publication Analysis
Top Keywords
mucosal nirsevimab
4
nirsevimab levels
4
levels respiratory
4
respiratory syncytial
4
syncytial virus
4
virus breakthrough
4
breakthrough bronchiolitis
4
mucosal
1
levels
1
respiratory
1
Similar Publications
Mucosal nirsevimab levels in respiratory syncytial virus breakthrough bronchiolitis.
Lancet Infect Dis
November 2024
CIRI-Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, CIC 1408 Vaccinology, F42023 Saint-Etienne, France; Immunology Department, University Hospital of Saint-Etienne, Saint-Etienne, France. Electronic address:
Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
J Virol
September 2020
Department of Molecular and Cellular Biochemistry, University of Kentucky, Lexington, Kentucky, USA
Article Synopsis
- RSV and HMPV are major causes of respiratory infections, especially in children, the elderly, and immunocompromised individuals, with a lack of approved treatments for HMPV and only palivizumab available for high-risk infants with RSV.* -
- Using 3-D human airway tissues, the study found RSV spreads more efficiently than HMPV and predominantly infects apical ciliated cells, while each virus displays different characteristics in their infection processes.* -
- Both palivizumab and nirsevimab inhibit RSV effectively, with nirsevimab showing greater potency, whereas 54G10 inhibited HMPV entry but not its spread, highlighting the distinct mechanisms of infection and treatment responses for each
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!